The relationship between emotion dysregulation and sleep in children and adolescents with ADHD: protocol for a systematic review

Introduction
Over half of children and adolescents with attention-deficit/hyperactivity disorder (ADHD) have difficulties with emotion dysregulation (EDR) and/or sleep, yet the interrelations between emotional regulation and sleep are not well-characterised in this population. This systematic review will address the relationship between these difficulties and investigate whether specific aspects of EDR are more strongly related to sleep problems in youth with ADHD.

Methods and analysis
We will adhere to the Preferred Reporting Items for Systematic Reviews and Meta-analysis guideline for systematic reviews. A wide set of electronic databases will be searched for peer-reviewed quantitative studies investigating the relationship between EDR and sleep in children and adolescents (ages 5 to 18 years) with ADHD. In addition, the reference list of all studies will be searched for other relevant studies, and Scopus will be used to search for citations of the included studies. We will also contact experts in the field to request published and unpublished studies. The primary outcome will be the effect size of the relationship between EDR and sleep in children and adolescents with ADHD. We will look at EDR and sleep broadly and also consider the multifaceted nature of both terms. Secondary outcomes will include which facets of EDR and sleep have been measured and how they have been measured, developmental differences between children and adolescents with ADHD and how—and the extent to which—studies controlled for the use of CNS medications and cooccurring disorders in their study design and/or statistical analyses. The quality and risk of bias of the included studies will be assessed using the Mixed Methods Appraisal Tool.

Ethics and dissemination
This protocol is for a review of studies and does not involve any new data collection and therefore does not need ethical or human subjects approval. The results will be presented at international conferences and in a peer-reviewed journal.

PROSPERO registration number
CRD42024612984.

Read More

Prescription Stimulant Misuse Affects About 1 in 4 Users

In recent years, clinicians in the US have increasingly prescribed amphetamine-type stimulants, most commonly to treat attention-deficit/hyperactivity disorder (ADHD). But a cross-sectional study published in JAMA Psychiatry found that among those taking prescription stimulants, about 25% reported using them outside of their intended purpose and 9% had prescription stimulant use disorder (PSUD), which causes clinically significant impairment or distress.

Read More